Overview of Dr. Zamarin
I am a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. My clinical and laboratory research is focused on the development of novel ways to use the immune system to treat cancer. In addition, I have a special interest in genetically engineered oncolytic viruses, an emerging class of immune therapeutic drugs. By manipulating the oncolytic viruses and the immune system, I’m exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies for gynecologic cancers.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2014
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2008 - 2010
Icahn School of Medicine at Mount SinaiClass of 2008
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2009 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Liz Tilberis Early Career Award Ovarian Cancer Research Alliance
- GOG Foundation Scholar Investigator Award GOG Foundation, 2019
- MSKCC Academic Excellence Recognition Award Memorial Sloan Kettering Cancer Center, 2018
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 1 citations
Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling.
Fang, Y., Xiao, X., Wang, J., Dasari, S., Pepin, D., Nephew, K., Mitra, A., Zamarin, D.> ;NPJ Precision Oncology. 2024 Jan 8 APR-246 increases tumor antigenicity independent of p53.
Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam M George, Daniel Thach, Zhong-Ke Yao, Ouathek Ouerfelli, Hengrui Liu, Brent R Stockwell, ...> ;Life Science Alliance. 2024 Jan 1Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment.
Nikhil I Khushalani, Kevin J Harrington, Alan Melcher, Praveen K Bommareddy, Dmitriy Zamarin> ;Molecular Therapy Oncolytics. 2023 Dec 19- Join now to see all
Journal Articles
A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Press Mentions
Key Advances and Advocacy Are Themes at SGO Annual MeetingMarch 21st, 2023
Dmitriy Zamarin, MD, PhD, on Novel Therapies for Cervical CancerMarch 23rd, 2022
Gynecologic Cancer Awareness Month: 2021 Immunotherapy Research UpdatesSeptember 3rd, 2021
- Join now to see all
Grant Support
- GOG Foundation Scholar Investigator AwardGOG Foundation2019–2024
- Profiling co‑evolution of ovarian cancer and its immune microenvironmentOvarian Cancer Research Alliance2020–2022
- Chromatin remodeling and immunotherapy in ovarian cancerOvarian Cancer Research Alliance2020–2022
- Novel approaches to locoregional and systemic immunotherapy for ovarian cancerCongressionally Directed Medical Research Programs: Ovarian Cancer Academy (OCA)2016–2021
Committees
- Chair, Translational Science, NRG Oncology Cervical Cancer Committee 2018 - Present
- Member, NRG Oncology Developmental Therapeutics Committee 2018 - Present
- Member, Institutional Biosafety Committee 2016 - Present
- Member, Protocol Development Committee 2015 - Present
- Member, Pharmacy and Therapeutics Committee, MSKCC 2014 - Present
